



# Delivering on Our Vision

## A Message from Our CEO

Our colleagues around the world truly exemplified the power that lies in collaboration, focus and resilience during our first full year as Viatriis. Despite the challenges of the ongoing pandemic, especially to the global supply chain, we remained agile and committed to delivering medicines to patients with little to no disruptions and protecting the safety, health and well-being of our colleagues.

Access is at the heart of our mission, and we marked several significant milestones in 2021 in expanding access to more affordable treatments. Together with our partner Atomo Diagnostics, we announced a multi-year agreement with global health agency Unitaid to expand access to HIV self-testing in low- and middle-income countries (LMICs). Together with our partner Biocor Biologics, we announced the launch of the first interchangeable biosimilar in the U.S., SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection, which provides more affordable options for the millions of Americans living with diabetes. We also received tentative FDA approval, and full approval in 2022, for the first generic version of Symbicort® for the treatment of asthma and chronic obstructive pulmonary disease (COPD) in partnership with Kindeva.

These examples highlight the impact of our Global Healthcare Gateway®, which opens our vast infrastructure to partners so we can collectively make a difference by broadening healthcare access.

As a signatory to the UN Global Compact (UNGC), we believe companies can be a force for good, and it is essential that we work to be enablers of potential solutions to some of society's most pressing challenges. As part of advancing our commitments and work in 2021, we endorsed the Women's Empowerment Principles and signed on to the UNGC CEO Water Mandate. To further progress our work, we have set company-wide goals in the areas of patient access, the environment, and diversity, equity and inclusion (DE&I). These goals are just a few examples of the work going on at every level of our organization to make a difference. You can read more details about these goals throughout this report.

We also used 2021 to establish a solid foundation for our future as a long-term partner in sustainable access to medicine. That work included a comprehensive strategic review to identify opportunities where we can add value, remove inefficiencies, simplify the

organization and reduce risk. In short, we are working to make Viatriis a simpler, stronger and more focused company. In doing so, we are positioning ourselves to develop more complex and novel products, providing greater opportunities to target gaps in patient care.

As I write this letter, I am also mindful of the crisis in Ukraine and the millions of people affected by conflicts around the world. We are working to support our employees and their families as well as the communities impacted while continuing to do all we can to supply essential medicines to patients in need.

With all that the world continues to face, making a difference as a company can come in many forms. Whether it has been supporting our own colleagues, managing partnerships to ensure a consistent supply of medicine for patients or setting goals that position us for a brighter future, I am proud of all that we have accomplished during our first year. And our story is just beginning. We hope you will continue to follow along in our journey.

Michael Goettler, CEO



*"Viatriis was launched with a clear focus on expanding access and ensuring a continued, reliable supply of medicine to patients in need. Even in the midst of the pandemic, the company was able to achieve this mission, while also meeting its financial commitments, progressing on integration activities and advancing efforts across key ESG topics. The Board of Directors recognizes the achievements of our outstanding global workforce in these areas during our first full year as Viatriis and continues to work closely and strategically with management to create a company that is well positioned for long-term success and to empower people worldwide to live healthier at every stage of life."*

— **Robert J. Coury**  
Executive Chairman, Viatriis